SI-BONE INC (SIBN)
US8257041090 - Common Stock
SI-BONE, Inc. Reports Financial Results for the First Quarter 2024
Annual guidance increased to $164 million - $166 million, implying annual growth of ~18% - 20%...
SI-BONE To Present at BofA Securities 2024 Healthcare Conference on May 14, 2024
SANTA CLARA, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
Notable Friday Option Activity: COIN, SIBN, DYN
SI-BONE To Report First Quarter 2024 Financial Results on May 6, 2024
SANTA CLARA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy today announced it will report financial results for the first quarter of 2024 after market close on Monday, May 6, 2024. Management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
SI-BONE Enters Oversold Territory (SIBN)
SI-BONE to Present at Barclays 26th Annual Global Healthcare Conference on March 12, 2024
SANTA CLARA, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
Oversold Conditions For SI-BONE (SIBN)
SI-BONE GAAP EPS of -$0.27 in-line, revenue of $38.9M beats by $0.31M (NASDAQ:SIBN)
SI-BONE reports Q4 2023 financial results, with revenue of $38.9M (+21.8% Y/Y) beating expectations.
SI-BONE, Inc. Reports Record Fourth Quarter and Full Year 2023 Financial Results and Issues 2024 Guidance
SANTA CLARA, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
SI-BONE To Report Fourth-Quarter and Full-Year 2023 Financial Results on February 26, 2024
SANTA CLARA, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
FDA clears smaller diameter SI-BONE Granite implant system (NASDAQ:SIBN)
SI-BONE (SIBN) said it has received FDA clearance for a smaller diameter of its iFuse Bedrock Granite Implant System for spinal procedures. Read more here.
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application
SANTA CLARA, Calif., Jan. 30, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc., (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to...
Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS
Cantor Fitzgerald picks AVITA Medical (RCEL) as its best 2024 medtech idea, while remaining bullish on AXGN, CERS, ELUT, XGN, NNOX, NPCE, NYXH, SIBN, and PACB. Read more here.
SI-BONE sees Q4 rev above estimate (NASDAQ:SIBN)
SI-BONE expects Q4 worldwide revenue of $38.5M-$38.7M, a 21% YoY increase, and Q4 U.S. revenue of $36.5M-$36.6M, up 22%.
SI-BONE Announces Preliminary Revenue for the Fourth Quarter and Full Year 2023
Fiscal Year 2023 revenue of $138.5 - $138.7 million representing growth of over 30%...
Commit To Buy SI-BONE At $17.50, Earn 19.1% Annualized Using Options
SI-BONE To Present at Piper Sandler 35th Annual Healthcare Conference on November 28, 2023
SANTA CLARA, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
SI-BONE is Now Oversold (SIBN)
SI-BONE To Present at Jefferies London Healthcare Conference on November 15, 2023
SANTA CLARA, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
SI-BONE to Report Third Quarter 2023 Financial Results on November 6, 2023
SANTA CLARA, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
Oversold Conditions For SI-BONE (SIBN)
SI-BONE, Inc. Announces iFuse Bedrock Granite® Implant System Compatibility with Certain Medtronic CD Horizon® Solera® 5.5/6.0 System Rods
SANTA CLARA, Calif., Sept. 05, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company focused on...
Despite a slower Q2, Needham sees medtech market growing 7% in 2023 (NYSE:BSX)
Needham sees the medtech sector growing by 7% in 2023 versus 5.7% last year, despite slowed growth in Q2, helped by double-digit growth in certain cardiology categories. Read more.
SI-BONE To Present at Morgan Stanley 21st Annual Global Healthcare Conference on September 12, 2023
SANTA CLARA, Calif., Aug. 29, 2023 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal...
Morgan Stanley bullish on SI-Bone, downgrades Stevanato, Integra, Agiliti (SIBN)
Morgan Stanley has added SI-Bone to its list of top medtech picks in the small-to-medium cap space, but downgraded Stevanato, Sight Sciences, Integra and Agiliti. Read more here.
Commit To Buy SI-BONE At $17.50, Earn 13.9% Annualized Using Options